EUVIMEDEUVIMED entdecken
Crossref

Identification of Novel Imidazo[1,2- b ]pyridazine Derivatives as Selective ROCK2 Inhibitors for the Treatment of Pulmonary Fibrosis

Zhi Cao, Shuqi Wang, Jiajun Ma, Jiyu Du, Xiujian Wei, Lingfeng Yue, Jiahao Zhang, Zehui Tan, Xin Zhai iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c02233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Zhi Cao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Hauptthemen laut MEDLINE: rho-Associated Kinases, Pyridazines, Pulmonary Fibrosis, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Liaoning Revitalization Talents Program, China Postdoctoral Science Foundation, Development Project of Ministry of Education Innovation Team.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rho-associated coiled-coil containing protein kinase 2 (ROCK2) has been identified as a promising target for the treatment of pulmonary fibrosis (PF). In this study, a series of novel imidazo[1,2-b]pyridazine derivatives were designed as selective ROCK2 inhibitors. Through comprehensive investigation of SARs, compounds A25 and A26 exhibited superior ROCK2 inhibitory potency (IC50 = 7.0 and 8.7 nM, respectively) and excellent isoform selectivity (SI = 200/138). In bleomycin-induced PF mice models, administration of A25 and A26 resulted in a pronounced reduction of collagen deposition and a significant reversal of fibrotic progression. Mechanism study confirmed that A25 exerted antifibrotic effects via the TGF-β/Smad and ROCK2/STAT3 signaling pathways. Furthermore, A25 exhibited a favorable safety profile, showing low hERG channel inhibition and almost no pathological alterations in major organs. Overall, A25 was identified as a promising lead compound for the development of selective ROCK2 inhibitors for PF therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

rho-Associated KinasesPyridazinesPulmonary FibrosisProtein Kinase InhibitorsImidazolesAnimalsMiceHumansStructure-Activity RelationshipMaleBleomycinMice, Inbred C57BL

Substanzen

rho-Associated KinasesPyridazinesProtein Kinase InhibitorsROCK2 protein, humanImidazolesBleomycinRock2 protein, mouse

Autor:innen und Institutionen

  • Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.

ORCID-Profile: Xin Zhai

Förderung

  • Liaoning Revitalization Talents Program
  • China Postdoctoral Science Foundation
  • Development Project of Ministry of Education Innovation Team

Zitieren

APA

Cao, Z., Wang, S., Ma, J., Du, J., Wei, X., Yue, L., Zhang, J., Tan, Z., & Zhai, X. (2025). Identification of Novel Imidazo[1,2- b ]pyridazine Derivatives as Selective ROCK2 Inhibitors for the Treatment of Pulmonary Fibrosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02233

Vancouver

Cao Z, Wang S, Ma J, Du J, Wei X, Yue L, et al. Identification of Novel Imidazo[1,2- b ]pyridazine Derivatives as Selective ROCK2 Inhibitors for the Treatment of Pulmonary Fibrosis. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02233

BibTeX
@article{Cao2025,
  author = {Cao, Zhi and Wang, Shuqi and Ma, Jiajun and Du, Jiyu and Wei, Xiujian and Yue, Lingfeng and Zhang, Jiahao and Tan, Zehui and Zhai, Xin},
  title = {Identification of Novel Imidazo[1,2- b ]pyridazine Derivatives as Selective ROCK2 Inhibitors for the Treatment of Pulmonary Fibrosis},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c02233}
}
Kostenlos starten →